Ultra-rare disease med back in stock, says Kedrion Biopharma

30 April 2024
lab_biotech_research_pipettes_big

USA-based Kedrion Biopharma has announced that Ryplazim (plasminogen, human-tvmh) is in stock and available for purchase in the USA.

The US regulator  announced in mid-2023 that the product was being provided “in a very limited supply” and would soon be out of stock.

The resumption of supply will be welcomed by the approximately 500 people in the USA with plasminogen deficiency type 1 (PLGD-1), an ultra-rare disease.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Biotechnology